Abstract Number: 1182 • 2018 ACR/ARHP Annual Meeting
The Disproportionate High Risk of Re-Fracture after Osteoporotic Treatment in Patients with Autoimmune Diseases
Background/Purpose: Patients with autoimmune diseases are associated with an increased risk of osteoporotic fracture. Anti-osteoporotic treatment could diminish re-fracture rates in post-menopause women. However, treatment…Abstract Number: 1584 • 2018 ACR/ARHP Annual Meeting
Evaluation of the Performance of the 2016 American College of Rheumatology-European League Against Rheumatism (Acr-Eular) Classification Criteria for Primary Sjogren`S Syndrome in Different Centers of Argentina
Background/Purpose: Primary Sjögren`s Syndrome (pSS) is a multisystemic, autoimmunity disease, characterized mainly by the hypofunction of the salivary and lacrimal glands, however the clinical spectrum…Abstract Number: 1771 • 2018 ACR/ARHP Annual Meeting
Long-Term Survival of Renal Transplantation in Rapidly Progressive Glomerulonephritis (RPGN). Study of 43 Cases from a Single Center
Background/Purpose: Rapidly Progressive Glomerulonephritis (RPGN) is characterized histology by presence of crescents and clinically by rapid and severe decline in kidney function. Thus, it may…Abstract Number: 1002 • 2017 ACR/ARHP Annual Meeting
Survival and Years of Potential Life Lost in Connective Tissue Disease and Vasculitis; Data from the Norwegian Connective Tissue Diseases and Vasculitis Registry (NOSVAR)
Background/Purpose: Survival is decreased in patients with connective tissue diseases (CTDs) and vasculitis, however few studies have compared the mortality between the specific diseases prospectively…Abstract Number: 2121 • 2017 ACR/ARHP Annual Meeting
Autoantibodies As Biomarkers for the Identification of Pre-Clinical Stages of Autoimmune Diseases: Demonstration of Inflammatory and Fibrotic Activity in the Liver of Asymptomatic and Biochemically Normal Individuals with Anti-Mitochondria Antibodies
Background/Purpose: Circulating autoantibodies precede clinical onset of several autoimmune diseases. The characteristics of the so-called pre-clinical stage of autoimmune diseases are poorly understood. Anti-mitochondria autoantibodies…Abstract Number: 1023 • 2017 ACR/ARHP Annual Meeting
The Autoimmune Discovery Ichip Distinguishes Healthy Individuals (HC) from Those with SLE, Rheumatoid Arthritis (RA), Scleroderma (SSc), Sjogren’s Syndrome (SS), and the Anti-Phospholipid Syndrome (APS)
Background/Purpose: Current serological tests are not sufficiently accurate in differentiating between HC and those with autoimmune rheumatic diseases. We developed the iCHIP antigen microarray to…Abstract Number: 2128 • 2017 ACR/ARHP Annual Meeting
A Systematic Review of the Management of Patients with Preexisting Rheumatologic Diseases Receiving Checkpoint Inhibitors for Cancer
Background/Purpose: The incidence and management of rheumatologic immune-related adverse events (irAEs) as a consequence of the checkpoint inhibitor (CPI) therapy in patients with cancer has…Abstract Number: 1064 • 2017 ACR/ARHP Annual Meeting
Characterization of Human Tolerogenic Dendritic Cells Generated with Protein Kinase C Inhibitor and Induction from Patients with Autoimmune Diseases
Background/Purpose: Tolerogenic dendritic cells (tDCs) are a promising therapeutic tool for specific induction of immunological tolerance. Human tDCs can be generated ex vivo using various…Abstract Number: 2142 • 2017 ACR/ARHP Annual Meeting
Autoantibodies Recognizing Cytosolic 5’-Nucleotidase 1A Are Associated with More Severe Disease in Patients with Juvenile Myositis
Background/Purpose: Autoantibodies recognizing cytosolic 5’-nucleotidase 1A (NT5C1A) are present in the sera of adults with myositis and other autoimmune diseases. They are especially prevalent in…Abstract Number: 1068 • 2017 ACR/ARHP Annual Meeting
Impact of TNF Antagonist Treatment on the Gut Microbiome In Vivo
Background/Purpose: Auto-immune diseases are in constant progression in the US. Biologic therapeutics have been used successfully to treat these diseases, but have presented some unique…Abstract Number: 2454 • 2017 ACR/ARHP Annual Meeting
Real-World Consistency of Response to Adalimumab over Time in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Background/Purpose: Adalimumab (ADA) was approved in the US in 2002 for rheumatoid arthritis (RA), and subsequently approved for the management of other inflammatory diseases such…Abstract Number: 1171 • 2017 ACR/ARHP Annual Meeting
Mycophenolate Mofetil May Improve Interstitial Pneumonia with Autoimmune Features
Background/Purpose: To assess the efficacy of mycophenolate mofetil (MMF) in treatment of adult patients with interstitial pneumonia with autoimmune features (IPAF). Methods: A retrospective medical…Abstract Number: 2601 • 2017 ACR/ARHP Annual Meeting
Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation in SLE Patient PBMC and in Trex1-/- Mouse Spleen and Heart
Background/Purpose: Type I interferon (IFN-I) is strongly implicated in the pathogenesis of Systemic Lupus Erythematosus (SLE) as well as rare monogenic ‘interferonopathies’ such as Aicardi-Goutieres…Abstract Number: 1290 • 2017 ACR/ARHP Annual Meeting
Preterm Birth Phenotypes in Women with Autoimmune Diseases
Background/Purpose: Systemic autoimmune diseases expose patients to chronic inflammation, immune dysregulation, and vascular abnormalities; complications that can impact obstetric outcomes. The goal of this study…Abstract Number: 2634 • 2017 ACR/ARHP Annual Meeting
The Prevalence of Autoimmune Disease in Families of Patients with Systemic Lupus Erythematosus (SLE). a Single Centre Study
Background/Purpose: Studies to date have reported that up to 30% of lupus patient have a first degree relative with an autoimmune disorder (AD). The most…
- « Previous Page
- 1
- …
- 70
- 71
- 72
- 73
- 74
- …
- 80
- Next Page »